Description

The USP16 Knockout SH-SY5Y Cell Line is a CRISPR/Cas9-edited knockout cell line derived from the SH-SY5Y human neuroblastoma cell line, designed to disrupt the USP16 gene. This model provides a stable loss-of-function system for investigating the role of the USP16 deubiquitinase in epigenetic regulation and neuroblastoma biology. By introducing a targeted gene disruption through CRISPR/Cas9 technology, this cell line enables researchers to study the functional consequences of USP16 ablation without off-target transgene expression.

SH-SY5Y cells are a widely used subclone of the SK-N-SH neuroblastoma line, originally isolated from a bone marrow biopsy of a pediatric neuroblastoma patient. These adherent cells exhibit a noradrenergic neuronal progenitor phenotype and retain the capacity to differentiate into mature neuron-like cells upon induction with retinoic acid or other neurotrophic factors. This makes SH-SY5Y an invaluable model for examining neuronal differentiation, neurodevelopmental signaling, and the molecular pathology of neuroblastoma. The cell line’s well-characterized genetic background and ease of culture further support its use in high-throughput and mechanistic studies.

The USP16 protein is a deubiquitinating enzyme with high specificity for histone H2A monoubiquitinated at lysine 119 (H2AK119ub), a mark catalyzed by the PRC1 complex. Deubiquitination by USP16 reverses this modification, alleviating PRC1-mediated transcriptional repression and enabling gene activation. USP16 physically interacts with PRC1 components Bmi1 and RING1B (RNF2) and influences the expression of downstream targets such as HOX gene clusters and genes essential for stem cell maintenance and differentiation. The enzyme’s activity is coupled with the broader Polycomb system, including PRC2 (marked by EZH2), thereby coordinating the dynamics of repressive chromatin states. The precise transcriptional regulation of USP16 remains undefined, but its enzymatic function places it as a key rheostat in H2A ubiquitination pathways.

In the SH-SY5Y neuroblastoma background, loss of USP16 leads to increased H2AK119 ubiquitination and enhanced PRC1-dependent gene silencing. This epigenetic shift can impair the transcriptional programs necessary for neuronal differentiation and may affect neuroblastoma cell growth characteristics. As a result, this knockout model enables dissection of how USP16-mediated deubiquitination balances Polycomb repression and activation during neural development and tumorigenesis. It is particularly suited for exploring the intersection between epigenetic dysregulation and neuroblastoma pathogenesis, offering insights into potential therapeutic vulnerabilities.

The USP16 Knockout SH-SY5Y Cell Line provides a versatile tool for a wide array of applications. Researchers can monitor H2AK119ub levels via Western blot and ChIP-qPCR, assess transcriptional changes in Polycomb target genes by RT-qPCR, and evaluate neuronal differentiation efficiency using retinoic acid-induced protocols. Functional assays for cell proliferation and apoptosis allow characterization of USP16’s role in cell fitness. Additionally, this line can be employed in high-throughput screening for small molecule modulators of USP16 activity or in combination with chemical inhibitors of Polycomb complexes. The model also facilitates studies of chromatin remodeling dynamics in neuroblastoma and other Polycomb-related contexts. For further information, please contact Ascent Research.